Who is sponsoring NCT05961696?

NCT05961696 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05961696?

Interventions in NCT05961696: Mosunetuzumab.

What condition does NCT05961696 study?

NCT05961696 studies Refractory B-cell Acute Lymphoblastic Leukemia.

Is NCT05961696 still recruiting?

NCT05961696 is currently withdrawn. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT05961696

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Withdrawn Phase 1 Last updated 10 October 2023

What this trial tests

Phase 1 trial testing Mosunetuzumab in Refractory B-cell Acute Lymphoblastic Leukemia. Withdrawn.

Timeline

5 July 2023

Primary endpoint
3 October 2023

3 October 2023

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	5 July 2023
Primary completion	3 October 2023
Estimated completion	3 October 2023
Sites	1 location across United States

Drugs / interventions tested

Mosunetuzumab (MOSUNETUZUMAB) — full drug profile →

Conditions studied

Refractory B-cell Acute Lymphoblastic Leukemia — all drugs for Refractory B-cell Acute Lymphoblastic Leukemia →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Refractory B-cell Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To find a recommended dose of mosunetuzumab that can be given to patients with ALL.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations.
Varon B, Horowitz NA, Khatib H. · · 2024 · cited 3× · PMID 39479221 · DOI 10.2147/ppa.s485838

Verify or expand the search:

Other trials of Mosunetuzumab

Trials testing the same drug.

NCT07278921 — Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at · recruiting
NCT07052695 — Mosunetuzumab for CLL MRD Clearance · Phase 1, PHASE2 · recruiting
NCT06948786 — Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Tri · Phase 2 · recruiting
NCT07031700 — A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL · Phase 2 · not yet recruiting
NCT06563505 — A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma · Phase 2 · recruiting

Other recruiting trials for Refractory B-cell Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT06179524 — CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05961696 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05961696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing